WO1981000409A1 - Intermediate compounds for preparation of morphine derivatives - Google Patents

Intermediate compounds for preparation of morphine derivatives Download PDF

Info

Publication number
WO1981000409A1
WO1981000409A1 PCT/US1980/000998 US8000998W WO8100409A1 WO 1981000409 A1 WO1981000409 A1 WO 1981000409A1 US 8000998 W US8000998 W US 8000998W WO 8100409 A1 WO8100409 A1 WO 8100409A1
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
amide
boron
carbon atoms
nalbuphine
Prior art date
Application number
PCT/US1980/000998
Other languages
French (fr)
Inventor
D Malfer
D Loncrini
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Priority to DE19803049763 priority Critical patent/DE3049763A1/en
Publication of WO1981000409A1 publication Critical patent/WO1981000409A1/en
Priority to DK151781A priority patent/DK151781A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Definitions

  • the invention relates to novel intermediate compounds useful in the preparation of morphine derivatives and to a process for preparing these compounds .
  • the compounds of the present invention are intermediates that may be reduced to form morphine derivative product compounds which do not possess known undesirable side effects of morphine, for example respiratory depression and the like.
  • These product compounds are of the type disclosed in Pachter et al; U. S. Patent 3,393,197; issued July 16, 1968, and such compounds may have the following general structural formula:
  • R is an aliphatic group.
  • a particularly useful compound selected from the above group is known as nalbuphine (wherein R in the formula is cyclobutyl).
  • oxycodone is deme hylated to form oxymorphone, for instance, as described in Wilson's U.S. Patent Application Serial No. 953,056, filed October 19, 1978, now international application No. PCT/US 79/008
  • the oxycodone-oxymorphone conversion, the first step in Figure 1, takes from about 3 to 18 hours at room temperature in the presence of a boron compound demethylating agent, or about 1 hour at about 190°C. in the presence of pyridine hydrochloride.
  • Oxymorphone is then converted to noroxymorphone which in turn is acetylated to form a eyelobutylamide intermediate (Ester Amide III).
  • Acetylation is accomplished by a reaction between cyclobutane carboxylic acid and ethyl chloroformate to form a mixed anhydride which subsequently reacts with noroxymorphone to form the ester amide which may be reduced with lithium aluminum hydride to form the product nalbuphine or a nalbuphine- type compound.
  • the present invention relates to an N- acyl-dihydro-14-hydroxynormorphone intermediate compound (herein Intermediate Amide II) useful in the preparation of nalbuphine and nalbuphine-type product compounds.
  • Intermediate Amide II has the following general structural formula:
  • R is a hydrocarbyl group of up to about 6 carbon atoms.
  • the substituent designated R in the structure of Intermediate Amide II is saturated and may have up to about 6 carbon atoms, preferably about 3 to 6 carbon atoms.
  • R may be alkyl of up to about 6 carbon atoms, preferably cycloalkyl of 3 to about 6 carbon atoms, e.g., cyclopropyl, cyclobutyl and cyclopentyl; especially cyclobutyl.
  • a new synthetic route, represented in Figure 2, for the preparation of nalbuphine and nalbuphine-type compounds from oxycodone has also been developed.
  • This route includes the preparation of the novel Intermediate Amide II compounds.
  • oxycodone is first converted in the presence of CNBr and sulfuric acid to noroxycodone which is in turn acylated, forming a first intermediate amide (Intermediate Amide I in Figure 2).
  • the first intermediate amide which need not be isolated, is then demethylated to form a second intermediate amide (Intermediate Amide II in Figure 2) which may be isolated and reduced to form the product nalbuphine or nalbuphine-type compounds.
  • nalbuphine and nalbuphine-type compounds can be produced in improved yields under milder reaction conditions and with shorter reaction times in comparison with known 0 synthesis procedures such as set forth in Figure 1.
  • R is as defined in the Intermediate Amide II structural formula above by reacting Intermediate Amide I with a demethylating agent under suitable conditions whereby the Intermediate Amide II is produced.
  • the reaction is conducted under demethylating conditions which may be mild, and the reaction may, for instance, be run at temperatures of from about 0° to 40°C.
  • a demethylating amount of a suitable agent is used, for instance, a boron compound.
  • the agent is capable of demethylating the methoxy group but incapable of forming numerous undesired byproducts.
  • the boron compounds include the boron halides such as boron tribromide, boron trichloride or the reaction product of such halides with alcohols, i.e., those containing 1 to 10 carbon atoms, preferably lower alcohols containing 1 to 6 carbon atoms, e.g., methanol, propanol, butanol, hexanol, etc.
  • the preferred demethylating agent is boron tribromide which is somewhat more active compared, for instance, to boron trichloride demethylating agent.
  • the demethylating agent may be present in an amount from about 2.5 to 8 moles, preferably about 3.5 to 6.5 moles, e.g. about 6 moles, of the demethylating agent per mole of Intermediate Amide I. No significant advantage is achieved by using somewhat more than about 8 moles. Utilizing less than about 2.5 moles may result in incomplete reaction.
  • the demethylating conditions include suitable reaction times, for example, from about 0.5 to 4 hours in batch procedures, and reaction temperatures, e.g., about 0°C. to 40°C, preferably about 15°C. to 25°C.-
  • the temperature of the reaction medium to which the demethylating agent may be added may be from about -25°C. to +20°C, preferably about +10°C. to +20°C.
  • reaction medium an essentially inert solvent that will not react with the demethylating agent, e.g., chlorobenzene.
  • the demethylating agent can be incorporated in the solvent and the solution combined with the Intermediate Amide I reactant.
  • the demethylating agent and solvent can be added to the reaction medium separately.
  • Intermediate Amide I can simply be mixed with the demethylating agent.
  • Recovery of Intermediate Amide II may be accomplished by simple precipitation with no further extraction being necessary to remove starting materials. This is a distinct advantage of the present invention as compared to other processes for preparing nalbuphine and nalbuphine-type compounds. Overall, yields of
  • -nalbuphine and nalbuphine-type compounds from oxycodone by the process of .the present invention may be approximately 40% or more versus 34% or less for the presently available processes.
  • the following examples illustrate the invention. All parts are by weight unless otherwise stated.
  • Table 1 illustrates additional runs which were conducted using procedures similar to those set forth in Examples II and III, although there were variations in temperature of addition of BBr.. and BC1-, temperature of reaction after addition, time of reaction and product yield, all as set forth in Table 1. Some of the results, especially in the earlier runs, are not consistent with results later achieved. The reasons for these discrepancies are not fully understood, although they can be attributed at least in part to a lack of experience in performing the reaction at the outset and to the fact that a material that was being isolated initially was not actually product material. In the later runs, as illustrated, good yields of product were achieved.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

N-acyl-dihydro-14-hydroxynormorphones such as N-(cycloalkylcarbonyl)-dihydro-14-hydroxynormorphones which are intermediates useful in the preparation of morphine derivatives that are both narcotic antagonists as well as analagetics. A process for preparing these intermediates is also disclosed.

Description

INTERMEDIATE COMPOUNDS FOR PREPARATION OF MORPHINE DERIVATIVES
The invention relates to novel intermediate compounds useful in the preparation of morphine derivatives and to a process for preparing these compounds .
The compounds of the present invention are intermediates that may be reduced to form morphine derivative product compounds which do not possess known undesirable side effects of morphine, for example respiratory depression and the like. These product compounds are of the type disclosed in Pachter et al; U. S. Patent 3,393,197; issued July 16, 1968, and such compounds may have the following general structural formula:
Figure imgf000003_0001
where R is an aliphatic group. A particularly useful compound selected from the above group is known as nalbuphine (wherein R in the formula is cyclobutyl).
A presently-used synthesis of nalbuphine and nalbuphine-type compounds from oxycodone, a readily available starting material, is represented in Figure 1. According to the processes, oxycodone is deme hylated to form oxymorphone, for instance, as described in Wilson's U.S. Patent Application Serial No. 953,056, filed October 19, 1978, now international application No. PCT/US 79/008 The oxycodone-oxymorphone conversion, the first step in Figure 1, takes from about 3 to 18 hours at room temperature in the presence of a boron compound demethylating agent, or about 1 hour at about 190°C. in the presence of pyridine hydrochloride. Oxymorphone is then converted to noroxymorphone which in turn is acetylated to form a eyelobutylamide intermediate (Ester Amide III). Acetylation is accomplished by a reaction between cyclobutane carboxylic acid and ethyl chloroformate to form a mixed anhydride which subsequently reacts with noroxymorphone to form the ester amide which may be reduced with lithium aluminum hydride to form the product nalbuphine or a nalbuphine- type compound.
Although this process has value, certain problems are associated with it. The oxycodone-oxymorphone conversion may be quite time-consuming and this is undesirable in a commercial process. The formation of the eyelobutylamide intermediate utilizing the reaction between cyclobutane carboxylic acid and ethyl chloroformate to form a mixed anhydride which subsequently reacts with noroxymorphone to form the amide, is a rather slow reaction. It would accordingly be highly desirable to use, for instance, cyclobutyryl chloride to form the amide directly, rather than the mixed anhydride, to give faster reaction times. Also, because of the complexity and side reactions of working with a noroxymorphone intermediate, a change in the order of reaction steps offers potential advantages in both yields and throughputs.
Accordingly, the present invention relates to an N- acyl-dihydro-14-hydroxynormorphone intermediate compound (herein Intermediate Amide II) useful in the preparation of nalbuphine and nalbuphine-type product compounds. Intermediate Amide II has the following general structural formula:
Figure imgf000005_0001
Intermediate Amide II
wherein R is a hydrocarbyl group of up to about 6 carbon atoms. In preferred embodiments of the present invention, the substituent designated R in the structure of Intermediate Amide II is saturated and may have up to about 6 carbon atoms, preferably about 3 to 6 carbon atoms. Thus R may be alkyl of up to about 6 carbon atoms, preferably cycloalkyl of 3 to about 6 carbon atoms, e.g., cyclopropyl, cyclobutyl and cyclopentyl; especially cyclobutyl.
A new synthetic route, represented in Figure 2, for the preparation of nalbuphine and nalbuphine-type compounds from oxycodone has also been developed. This route includes the preparation of the novel Intermediate Amide II compounds. According to this new synthesis, oxycodone is first converted in the presence of CNBr and sulfuric acid to noroxycodone which is in turn acylated, forming a first intermediate amide (Intermediate Amide I in Figure 2). The first intermediate amide, which need not be isolated, is then demethylated to form a second intermediate amide (Intermediate Amide II in Figure 2) which may be isolated and reduced to form the product nalbuphine or nalbuphine-type compounds. The demethylation of the Intermediate Amide I material to the Intermediate Amide II materials is a major departure from previous schemes for the preparation of nalbuphine and nalbuphine-type compounds, and the Intermediate Amide II materials are novel compounds. By utilizing this new synthesis route involving the novel intermediate amides of the present invention, nalbuphine and nalbuphine-type compounds can be produced in improved yields under milder reaction conditions and with shorter reaction times in comparison with known 0 synthesis procedures such as set forth in Figure 1.
In accordance with this new demethylation process the methyl group is removed from the methoxy substituent of a first intermediate amide compound (Intermediate Amide I) having the following structural formula:
Figure imgf000006_0001
Intermed iate Amide I
5 wherein R is as defined in the Intermediate Amide II structural formula above by reacting Intermediate Amide I with a demethylating agent under suitable conditions whereby the Intermediate Amide II is produced. The reaction is conducted under demethylating conditions which may be mild, and the reaction may, for instance, be run at temperatures of from about 0° to 40°C.
Isolation of the Intermediate Amide II is simple and straightforward, and it may be accomplished by simple precipitation with no further extraction necessary to remove starting material (ethers). This single separation is in marked contrast to the separation of other phenol-containing compounds of this general type from their corresponding ethers. The overall yield of morphine-type product from the oxycodone starting material may be as much as about 40% or more which is an improvement over the oxycodone- oxymorphone type process described above and in Figure 1.
In preparing the Intermediate Amide II compounds, a demethylating amount of a suitable agent is used, for instance, a boron compound. The agent is capable of demethylating the methoxy group but incapable of forming numerous undesired byproducts. The boron compounds include the boron halides such as boron tribromide, boron trichloride or the reaction product of such halides with alcohols, i.e., those containing 1 to 10 carbon atoms, preferably lower alcohols containing 1 to 6 carbon atoms, e.g., methanol, propanol, butanol, hexanol, etc. The preferred demethylating agent is boron tribromide which is somewhat more active compared, for instance, to boron trichloride demethylating agent. The demethylating agent may be present in an amount from about 2.5 to 8 moles, preferably about 3.5 to 6.5 moles, e.g. about 6 moles, of the demethylating agent per mole of Intermediate Amide I. No significant advantage is achieved by using somewhat more than about 8 moles. Utilizing less than about 2.5 moles may result in incomplete reaction.
The demethylating conditions include suitable reaction times, for example, from about 0.5 to 4 hours in batch procedures, and reaction temperatures, e.g., about 0°C. to 40°C, preferably about 15°C. to 25°C.- In this regard the temperature of the reaction medium to which the demethylating agent may be added may be from about -25°C. to +20°C, preferably about +10°C. to +20°C. After Intermediate Amide I and the demethylating agent are combined the heat of reaction may result in an increase in the temperature of the reaction medium, although the temperature may be controlled to avoid undue temperature increases. Higher temperatures of the reaction medium may result in lower yields of the Intermediate Amide II product. It may be advantageous in this regard to provide in the reaction medium an essentially inert solvent that will not react with the demethylating agent, e.g., chlorobenzene. The demethylating agent can be incorporated in the solvent and the solution combined with the Intermediate Amide I reactant. Alternatively, the demethylating agent and solvent can be added to the reaction medium separately. For example, Intermediate Amide I can simply be mixed with the demethylating agent. Recovery of Intermediate Amide II may be accomplished by simple precipitation with no further extraction being necessary to remove starting materials. This is a distinct advantage of the present invention as compared to other processes for preparing nalbuphine and nalbuphine-type compounds. Overall, yields of
-nalbuphine and nalbuphine-type compounds from oxycodone by the process of .the present invention may be approximately 40% or more versus 34% or less for the presently available processes. The following examples illustrate the invention. All parts are by weight unless otherwise stated.
EXAMPLE I
PREPARATION OF INTERMEDIATE AMIDE I
To a 500 ml flask are added 200 ml of anhydrous tetrahydrofuran (THF) and 6.5 g of ethylchloroformate. The mixture is cooled to 5°C. To this flask, a mixture containing 6 g of cyclobutane carboxylic acid, 8.5 ml of triethyla ine and 50 ml of THF is slowly added. The temperature should not rise above 10°C. during this
- OTM fPoIr addition. With stirring, the mixture is allowed to rise to 20-25°C. over a 1-2 hr period. The triethylamine salt is filtered off and 14 gms of noroxycodone and 1.5 ml of triethylamine are added to the solution. The mixture is stirred for 1-2 hrs at room temperature. The THF is evaporated and the resulting product is diluted to 200 ml with chlorobenzene.
EXAMPLE II CLEAVAGE OF INTERMEDIATE AMIDE I WITH BORON TRIBROMIDE
One hundred milliliters of the Intermediate Amide I solution as prepared in Example I are added to a 500 ml flask and cooled to 10°-15°C. A mixture containing 100 ml of chlorobenzene and 6-11 ml of BBr-, is slowly added to the flask such that the temperature of the mixture should not rise above 20°C. The molar ratio of BBr,. to Intermediate Amide I in the flask can range from about 2.8 to 5.1:1. The mixture is stirred at 20- 25°C. for 30 minutes and quenched by adding the mixture to 300 ml of ice water. The solid is filtered off, washed with chlorobenzene and air dried. The solid is then slurried in methanol, filtered, washed again with methanol and dried. The solid recovered weighs 4.4 to 4.9 grams, representing 51 to 57% yields based on noroxycodone.
EXAMPLE III
CLEAVAGE OF INTERMEDIATE AMIDE I WITH BORON TRICHLORIDE
One hundred milliliters of the Intermediate Amide I solution as prepared in Example I are added to a 500 ml flask and cooled to 10-15°C. While cooling such a solution, a solution of boron trichloride is prepared by introducing boron trichloride gas to 100 ml of
OMPI - 8 -
chlorobenzene. The boron trichloride solution so formed is added to the Example I cooled solution keeping the temperature below 20°C. The molar ratio of BCl^ to Intermediate Amide A in the flask is about 7.7:1. The reaction mixture is stirred for four hours at 20°-25°C. and quenched in 300 ml of ice water. Solid is filtered off, washed with chlorobenzene and air dried. The solid is then slurried in methanol, filtered, washed again with methanol and dried. The solid recovered weighs 3.6 4.0 grams, representing a 42-47% yield based on noroxycodone.
EXAMPLES IV - XIX
TEMPERATURE, CONCENTRATION AND REACTION TIME VARIATION
Table 1 illustrates additional runs which were conducted using procedures similar to those set forth in Examples II and III, although there were variations in temperature of addition of BBr.. and BC1-, temperature of reaction after addition, time of reaction and product yield, all as set forth in Table 1. Some of the results, especially in the earlier runs, are not consistent with results later achieved. The reasons for these discrepancies are not fully understood, although they can be attributed at least in part to a lack of experience in performing the reaction at the outset and to the fact that a material that was being isolated initially was not actually product material. In the later runs, as illustrated, good yields of product were achieved.
- RE
OϊvP ^ 1P Table 1.
Figure imgf000011_0001
Run Mole Ratio Temperature Temperature Time of Amide II Amide II
Number of BBr3 Addition of of Reaction Reaction Product Product (BC13 if BBr3 (BCI3) After Addi¬ After Addi¬ Yield from Yield from . Stated) to to Mixture tion tion of Amide I Noroxycodone ■ Amide I BBr3 (BCI3) i IV 3.6 6 to 20°C 27°C 4 hrs 1% —
V 3.6 15 to 24°C 27°C 3 hrs ca. 1% —
',' VI 3.6 8 to 10°C 5-6°C 1 hr 55% 34%
' VII 4 5 to 9°C 4°C 1 hr 35% 21.7%
VIII 2.6 8 to 12°C 27-30°C 4 hrs 39% 24.2%
IX 2.96 6 to 9°C 4-10°C 11 in 31% • 19.2% !' X 3.1 8 to 15°C 7°C 1 hr 10 min 38.5% 23.9%
1, XI 3.8 (BCl ) 6 to 11°C 10-12°C 4 hrs 55 min 1% --
XII 6 0 to -20°C 0-2°C 54 min 52% 32%
1 XIII 6 -16 to -12° C 0°C 64 min 55% 34% σ XIV 6 -24 to -20° C 0°C 34 min 65% 41%
1 XV 8 -18 to -25° C 0°C 15 min not isolated 55%
XVI 8 +15 to +17° C 20°C 30 min not isolated 49%
XVII 4 +15 to +18° C 20°C 30 min not isolated 50%
XVIII 2.6 +15 to +18° C 20°C 30 min not isolated 19%
XIX 7.0 +10 to +16° C 20-25°C 4 hrs not isolated 42%

Claims

WHAT IS CLAIMED IS:
1. Compounds useful in the preparation of nalbuphine and nalbuphine-type product compounds, said compounds being characterized by the following structural formula
Figure imgf000012_0001
wherein R is hydroearbyl of up to about 6 carbon atoms.
2. The compounds of claim 1 characterized in that R is saturated and contains from about 3 to 6 carbon atoms.
3. The compounds of claim 2 characterized in that R is selected from cyclopropyl, cyclopentyl and cyclobutyl.
4. A compound of claim 3 characterized in that R is cyclobutyl.
5. A process for producing amide compounds having the following structural formula
Figure imgf000012_0002
wherein R is hydroearbyl of up to about 6 carbon atoms, which process is characterized by reacting a first amide having the following structural formula
Λ, ~"wip
Figure imgf000013_0001
wherein R is hydroearbyl of up to about 6 carbon atoms, with a demethylating amount of a boron compound demethylating agent in a reaction medium under demethylating conditions.
6. A process according to claim 5 characterized in that the boron compound demethylating agent is selected from the group consisting of boron tribromide, boron trichloride and the reaction products of such halides with a lower alcohol and is used in an amount to provide from about 2.5 to about 8 moles of the boron compound per mole of said first amide compound.
7. A process according to claim 6 characterized in that said boron compound is boron tribromide or boron trichloride.
8. A process according to.claim 7 characterized in that the demethylating conditions include temperatures of from about 0° to about 40°C.
9. A process according to claims 5, 6, 7 or 8 characterized in that R is saturated and contains from about* 3 to 6 carbon atoms.
10. A process according to claims 5, 6, 7 or 8 characterized in that R is selected from the group consisting of cyclopropyl, cyclobutyl and cyclopentyl.
11. A process according to claims 5, 6, 7 or 8 characterized in that R is cyclobutyl.
"_fUREΛ~
O PI
PCT/US1980/000998 1979-08-09 1980-08-07 Intermediate compounds for preparation of morphine derivatives WO1981000409A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19803049763 DE3049763A1 (en) 1979-08-09 1980-08-07 INTERMEDIATE COMPOUNDS FOR PREPARATION OF MORPHINE DERIVATIVES
DK151781A DK151781A (en) 1979-08-09 1981-04-03 INTERMEDIATE PRODUCTS FOR MORPHININE DERIVATIVES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6527579A 1979-08-09 1979-08-09
US65275 1993-05-21

Publications (1)

Publication Number Publication Date
WO1981000409A1 true WO1981000409A1 (en) 1981-02-19

Family

ID=22061564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1980/000998 WO1981000409A1 (en) 1979-08-09 1980-08-07 Intermediate compounds for preparation of morphine derivatives

Country Status (16)

Country Link
JP (1) JPS56501010A (en)
AU (1) AU6116580A (en)
BE (1) BE884671A (en)
DD (1) DD154541A5 (en)
DK (1) DK151781A (en)
ES (1) ES8104296A1 (en)
FI (1) FI802479A (en)
FR (1) FR2465735A1 (en)
GB (1) GB2066256A (en)
IL (1) IL60783A0 (en)
IT (1) IT8068267A0 (en)
NL (1) NL8020319A (en)
NO (1) NO802139L (en)
PL (1) PL226162A1 (en)
SE (1) SE8102214L (en)
WO (1) WO1981000409A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
WO1991005768A1 (en) * 1989-10-16 1991-05-02 The United States Of America, Represented By The Secretary, United States Department Of Commerce Total synthesis of northebaine, normorphine, noroxymorphone enantiomers and derivatives via n-nor intermediates
US5668285A (en) * 1986-10-31 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2772270A (en) * 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) * 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3249616A (en) * 1966-05-03 Ix-dfflydroxy-g-oxo-n-phenethylmor- phinan (cis) and production thereof
US3299072A (en) * 1962-10-10 1967-01-17 Smith Kline French Lab Thebaine derivatives
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
CA913077A (en) * 1972-10-24 J. Pachter Irwin Process of preparing n-substituted 14-hydroxydihydronormorphines
US3775414A (en) * 1972-05-10 1973-11-27 Bristol Myers Co Process for the preparation of 14-hydroxymorphinan derivatives
US4161597A (en) * 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7106612A (en) * 1971-05-13 1972-11-15 N-cycloalkylalkyl-14-hydroxy-dihydronormorphines - - by o-demethylation of 14-methoxy cpds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249616A (en) * 1966-05-03 Ix-dfflydroxy-g-oxo-n-phenethylmor- phinan (cis) and production thereof
CA913077A (en) * 1972-10-24 J. Pachter Irwin Process of preparing n-substituted 14-hydroxydihydronormorphines
US2772270A (en) * 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) * 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3299072A (en) * 1962-10-10 1967-01-17 Smith Kline French Lab Thebaine derivatives
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3775414A (en) * 1972-05-10 1973-11-27 Bristol Myers Co Process for the preparation of 14-hydroxymorphinan derivatives
US4161597A (en) * 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Chemical Reviews, Volume 58, issued 1958, Gerrard, et al, Reactions of Boron Trichloride with Organic Compounds, see Pages 1091-1095 *
Heterocycles, Volume 6, no. 7, issued 1977, Mohamed F. Rahman, et al, Preparation and Analgesic Activity of Some 3,4-Disubstituted N-Methylmorphinans of the (-) Series, pages 881-885 *
Journal of Medicinal Chemistry, volume 20, no. 1, issued January, 1977, Kenner C Rice, A Rapid, High Yield Conversion of Codeine to morphine, pages 164-165 *
Journal of Medicinal Chemistry, Volume 21 number 4, issued April, 1978, Ikuo Iijima, et al, Studies in the (+)-morphinan-Series, 5,1 synthesis and Biological properties of (+)-Nalaxone, pages 398-400 *
Journal of Organic chemistry, Volume 43, number 4, issued 1978, Arnold A Liebman et al, preparationaand crystal structure of 6-acetyl-1- Iodocodeine, Pages 737-739 *
Journal of the American Chemical Society Volume 95, No. 23, issued 14 November 1973, I.Monkovic, et al, Total synthesis and pharmacological Activities of N-substituted 3,,14-Dihydroxymorphinans 1, pages 7910-7912. *
Journal of the Chemical Society, issued 1960, T.G. Bonner, et al, Dealkylation and deacylation of carbohydrate Derivatives with Boron Trichloride and Boron Tribromide pages 2929-2934 *
Menard, et al, Canadian Journal of Chemistry, Volume 54, issued 1976, Marcel Menard, et al, Ring C substituted 14-hydroxymorphinans and isomorphinans as narcotic antagonists, pages 429-439 *
Synthetic Communications, Volumne 9, number 5, issued 1979, Jeffery B. Press, Deethylation of Aryl Ethyl Ethers by Boron Tribomide pages 407-410 *
Tetrahedron Letters, No. 20, issued 1972, Pergamon Press, Great Britain, Carmelo Gandolfi, et al, Prostaglandins: By-Products in BBr3-Cleavage of Coreys Methylether Intermediate, pages 2063-2065 *
Tetrahedron Letters, No. 24, issued 1968 Pergamon Press, Great Britain, J.F.W. McOmie et al, Demethylation of Aryl Methyl Ethers by Boron Tribromide, pages 2289-2292 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5668285A (en) * 1986-10-31 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates
WO1991005768A1 (en) * 1989-10-16 1991-05-02 The United States Of America, Represented By The Secretary, United States Department Of Commerce Total synthesis of northebaine, normorphine, noroxymorphone enantiomers and derivatives via n-nor intermediates

Also Published As

Publication number Publication date
NO802139L (en) 1981-02-10
IT8068267A0 (en) 1980-08-07
ES494122A0 (en) 1981-04-16
IL60783A0 (en) 1980-10-26
DD154541A5 (en) 1982-03-31
PL226162A1 (en) 1981-04-24
SE8102214L (en) 1981-04-07
NL8020319A (en) 1981-07-01
BE884671A (en) 1980-12-01
DK151781A (en) 1981-04-03
FR2465735A1 (en) 1981-03-27
ES8104296A1 (en) 1981-04-16
AU6116580A (en) 1981-02-12
JPS56501010A (en) 1981-07-23
FI802479A (en) 1981-02-10
GB2066256A (en) 1981-07-08

Similar Documents

Publication Publication Date Title
CN102516345B (en) Preparation method of ulipristal acetate and key intermediate thereof
JPH01305077A (en) Preparation of vacatine 111 and 10- deacetylvacatine 111 derivative
CA2709971A1 (en) Solid and crystalline dutasteride and processes for preparation thereof
CN114805314A (en) Synthesis method of Ensaitevir
WO1981000409A1 (en) Intermediate compounds for preparation of morphine derivatives
AU630013B2 (en) Improved method of preparing an intermediate for the manufacture of bambuterol
JPH05238990A (en) 1,4,5,8-tetrakis(hydroxymethyl)naphthalene derivative and its production
EP0911335B1 (en) Method for producing furopyridine derivatives and intermediate compounds
JPS6332796B2 (en)
USRE31260E (en) Process for the preparation of an acetonitrile derivative
JP2003512297A (en) Method for producing aliphatic fluoroformate
JP2815654B2 (en) Novel 4-substituted-3,5-dimethylpicolinic acid compound and method for producing the same
US4153631A (en) Process for processing silver halide developing agents
JPS6212770B2 (en)
CN114057684B (en) Synthesis method of tiotropium bromide intermediate methyl bis (2-dithienyl) glycolate
US2799703A (en) Manufacture of propiolic acid
JPH0137397B2 (en)
JPS6026395B2 (en) Synthesis method of N-trialkylsilylmethylurea
JP2743198B2 (en) Cyclopentanes
US4017501A (en) Process for preparing pyridinium chloride salts of alkyl esters of 2-chloro-N-2-hydroxyethylacetamide
JPS6343382B2 (en)
US2591313A (en) Process for producing alpha
CA1049035A (en) Process for the preparation of triesters and products thus obtained
KR0173315B1 (en) Novel process for producing 6-acyl-7-deacetylforskolin derivatives
KR860000263B1 (en) Process for the preparation of di-substituted nitriles from accto nitrile

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AT CH DE DK GB JP NL SE SU

ENP Entry into the national phase

Ref document number: 1980 9083

Country of ref document: AT

Date of ref document: 19810219

Kind code of ref document: A

TCAT At: translation of claims filed
RET De translation (de og part 6b)

Ref document number: 3049763

Country of ref document: DE

Date of ref document: 19820304

WWE Wipo information: entry into national phase

Ref document number: 3049763

Country of ref document: DE